|View printer-friendly version|
|Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate|
PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire via COMTEX/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem(R) (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy." The new patent, number 7,851,506, is also listed in the FDA's Approved Drug Products List (the Orange Book).
In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product's formulation and Jazz Pharmaceuticals' distribution system. Six issued patents are now listed in the Orange Book. These patents expire from 2019 to 2024.
"Enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, Jazz Pharmaceuticals' intent to vigorously enforce its intellectual property rights. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to protect its intellectual property and defend its patents, the possible introduction of generic products, the dependence of the company on sales of Xyrem, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere inJazz Pharmaceuticals'Securities and Exchange Commission filings and reports, including in itsQuarterly Report on Form 10-Q for the quarter ended September 30, 2010 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 5, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
SOURCE Jazz Pharmaceuticals, Inc.